KR100780846B1 - The Method for Manufacturing Polyurethane Foam Dressing that comprises a separate layer including drugs - Google Patents

Abstract

The present invention relates to a method for producing a polyurethane foam dressing material having a drug-containing layer so that it can be used on wounds that may be infected or infected, in particular, the formation of a separate drug-containing layer separated from the polyurethane foam layer, the presence or absence of exudate Regardless of the amount of the present invention relates to a polyurethane foam dressing material that can be supplied to the wound surface smoothly. Method for producing a polyurethane foam dressing material of the present invention comprises the steps of preparing a non-porous waterproof polyurethane film layer; Obtaining a polyurethane foam layer in a gel state with a tack property; Laminating a polyurethane foam layer and a polyurethane film layer in a gel state; It includes; forming a drug-containing layer. Polyurethane foam dressing material according to the present invention, it is possible to smoothly release the drug through a separate drug-containing layer separated from the foam layer can prevent the waste of the drug due to the excessive addition, the drug regardless of the presence or absence of exudate Can be released to provide a sufficient amount of medication to the wound, even in the case of wounds with little or no exudate or late in the wound.

Dressings, polyurethanes, wounds, cuts, antimicrobials, drugs, drug layers

Description

Polyurethane foam dressing material having a drug-containing layer and a method for manufacturing the same {The Method for Manufacturing Polyurethane Foam Dressing that comprises a separate layer including drugs}

1A to 1F are schematic views of a polyurethane foam dressing material according to the present invention.

2a to 2c are scanning electron micrographs of the polyurethane foam dressing material according to the present invention.

Figure 3 is a graph showing the drug release behavior of each sample with different concentrations of antimicrobial agents and preparation methods.

<Description of Symbols for Major Parts of Drawings>

10: foam layer with open cells

11: wound surface contact layer 12: internal absorption layer

P: Pore 20: Non-porous waterproof outer film layer

30: drug containing layer

The present invention relates to a method for producing a polyurethane foam dressing material having a drug-containing layer so that it can be used on wounds that may be infected or infected, in particular, the formation of a separate drug-containing layer separated from the polyurethane foam layer, the presence or absence of exudate Regardless of the amount of the present invention relates to a polyurethane foam dressing material that can be supplied to the wound surface smoothly.

The treatment of wounds is the basis of medicine and has a long history. According to Papyrus, animal oil, honey, and cotton have been used to treat wounds since 5000 BC. Throughout history, many changes have been made in the treatment of wounds. In 1962, zoologist Winter published a research paper stating that keeping the wounds wet helps to heal rather than drying the wounds to scab. Since Winter's paper, the utility of wet wound care has been continuously demonstrated and emphasized. Wet-environmental wet dressing methods that prevent body fluids from wounds from being dehydrated or dried today have been found to facilitate wound healing.

The ideal dressing material should maintain a moist environment between the wound and the dressing material, have adequate absorbency and moisture permeability, prevent drying of the wound surface and avoid the swelling of the surrounding normal skin. In addition, it should have functionalities such as gas exchange and prevention of invasion of bacteria from the outside, and should not stick to the wound surface and cause damage to new tissues or the like. In addition, it can be an ideal dressing material if the wound healing state can be easily observed, non-irritating, easy to use and economical. However, there is no dressing material that satisfies all of these ideal conditions, and research and development on new dressing materials are continued to satisfy these conditions.

The dressing materials that have been used relatively recently are as follows. In the early 1970s, “OpSite ™”, a translucent transparent film, promoted wound healing by promoting the dissolution of necrotic tissue and the formation of granulation tissue by keeping the wound moist. However, OpSite ™ has a problem in that excessive skin exudates around the wound, so that the surrounding skin becomes crushed, and the exudates leak out and have to be discharged randomly.

In 1982, a product called “DuoDERM ™” was introduced in the United States, a hydrocolloid dressing that, when attached to the wound, reacted with exudate to provide a gel-type moist environment to promote epithelialization of wounds. However, there is a disadvantage in that excessive exudates are accumulated because gas and water vapor such as oxygen or carbon dioxide do not pass, and gel may remain on the wound surface during dressing exchange.

Dressing materials using polymers have been mainly produced by the gelation method, but recently, a foam manufacturing method for forming open pores by foaming synthetic polymers such as polyurethane is also used. In US Pat. Nos. 5,674,917 and 5,744,509, super absorbent polymers have been added to provide a high absorbency to the polyurethane foam. However, this is because after absorbing the exudates, the super absorbent polymer swells, causing volume expansion of the foam dressing material, which puts pressure on the wound surface, and when the pressure is applied to the dressing, the super absorbent polymer is applied. It may not come out or remain as a residue on the wound surface, which has a problem that adversely affects the healing of the wound, which is not suitable for use as a dressing material.

In addition, we have introduced a polyurethane foam dressing material containing drugs for use in wounds that are already infected or may be infected, as well as creating a moist environment to smooth wound healing. In the Republic of Korea Patent No. 10-0404140, polyurethane foam dressing by mixing and stirring a polyurethane prepolymer having an isocyanate end, a crosslinking agent, a foaming agent, an antibacterial agent and an additive, and then injecting the foam into a mold. A method of making ash is described.

However, as described above, the foam itself, that is, the method of including the drug inside the foam has some problems as follows due to the structural characteristics of the polyurethane foam made of porous. First, the drug inside the cell of the polyurethane foam is released out and touches the wound surface, so that the drug can be shown.In the early stage, a large amount of exudate results in swelling of the foam dressing material by a large amount of exudate. In the late middle and late stages, the drug is not released well. Therefore, the release amount and the release of the drug is greatly affected by the amount of exudate, so the release behavior becomes unstable, and the difference due to the wound is large. Secondly, due to this difficulty of release, more than necessary amount of drug should be added to the foam, nevertheless, the drug may not be smoothly supplied to the wound. Third, in the case of wounds without exudate, even if the drug is contained in the foam, the drug is not released to the wound surface, and thus does not exhibit drug efficacy.

The present invention is to solve the conventional problems as described above, the present invention for the purpose of providing a polyurethane foam dressing material that can supply the drug smoothly to the wound surface regardless of the presence or absence of exudate. do.

To this end, in the present invention,

(a) 20 to 70 parts by weight of methyl ethyl ketone, 5 to 30 parts by weight of dimethylformamide, and 1 to 10 parts by weight of pigment are added to 100 parts by weight of polyurethane resin, followed by stirring, removing bubbles and coating on a release paper, followed by drying. Obtaining a non-porous waterproof polyurethane film layer;

(b) A foam mixture obtained by mixing 60 to 120 parts by weight of deionized water (DIW) and 1 to 10 parts by weight of surfactant at a high speed to 100 parts by weight of polyurethane prepolymer on a release paper with a thickness of 0.05 to 10 mm before curing. Obtaining a polyurethane foam layer in a gel state having a tack property;

(c) The polyurethane film layer obtained in (a) and the polyurethane foam layer in the gel state obtained in (b) are laminated, hot-air dried, cooled to room temperature, and then contacted with the polyurethane film layer and the foam layer. Peeling the release paper to obtain a polyurethane foam dressing material; And

(d) a polyurethane foam having a drug containing layer comprising applying a solution containing a drug at a viscosity of 2,000 to 4,000 cps / 25 ° C. to the foam layer of the polyurethane foam dressing material obtained in (c) above to form a drug containing layer. A method for producing a dressing material is provided.

Other objects and advantages of the present invention will be described below and will be better understood by practice of the present invention.

Method for producing a polyurethane foam dressing material of the present invention comprises the steps of preparing a non-porous waterproof polyurethane film layer; Obtaining a polyurethane foam layer in a gel state with a tack property; Laminating a polyurethane foam layer and a polyurethane film layer in a gel state; It includes; forming a drug-containing layer.

Production of non-porous waterproof polyurethane film layer

To 100 parts by weight of polyurethane resin, 20 to 70 parts by weight of methyl ethyl ketone, 5 to 30 parts by weight of dimethylformamide, and 1 to 10 parts by weight of pigment are added to the mixture, followed by stirring. A waterproof polyurethane film layer is made. In one embodiment of the present invention by degassing with a vacuum stirring deaerator to remove bubbles. The foamed polyurethane solution is coated on a matte release paper using a coating gauge or the like and then dried to obtain a non-porous waterproof polyurethane film layer. Preferably, a hydrophilic polyurethane resin having a hydrophilic group introduced into the polyurethane resin is used. Thus performing this step using a hydrophilic polyurethane resin to obtain a polyurethane film layer having both moisture permeability and waterproofness, this moisture-permeable water-resistant film layer forms the outer side of the dressing material produced according to the present invention.

The pigment is a known organic or inorganic pigment using a polyurethane resin as a vehicle and a solvent composed of methyl ethyl ketone and dimethylformamide. Preferably organic pigments are used.

Polyurethane Foam  Produce

(1) Preparation of Polyurethane Prepolymer

First, isocyanate is added to a mixed solution of polyol and diol to react to prepare a polyurethane prepolymer.

Specific preparation examples of the polyurethane prepolymer are as follows. First, polyols and diols were added and stirred at a stirring speed of about 150 RPM, and the temperature was raised to 50 ° C, followed by stirring for 30 minutes, followed by addition of isocyanate, followed by reaction until the NCO content (%) reached the theoretical value under nitrogen atmosphere. Let's do it.

Examples of the polyol include polypropylene oxide glycol; Polyethylene oxide glycol; Polytetramethylene ether glycol; Ethylene oxide / propylene oxide copolymers; Polytetrahydrofuran / ethylene oxide copolymers; Polytetrahydrofuran / propylene oxide copolymers; Polybutylene carbonate glycol; Polyhexamethylene carbonate glycol; Polycaprolactone glycol; Polyethylene adipate; Polybutylene adipate; Polyneopentyl adipate; Polyhexamethylene adipate and the like may be used alone or in combination of two or more thereof. Preferably, a polyethylene oxide glycol having a molecular weight of 500 to 6,000 and two or more hydroxyl groups and a polypropylene oxide glycol are mixed at a molar ratio of 4: 6 to 8: 2 or an ethylene oxide content of 20 to 90 Ethylene oxide / propylene oxide copolymers are used in%.

As the isocyanate, aromatic, aliphatic and substituted isocyanates or mixtures thereof may be used. For example, 2, 4- toluene diisocyanate; 2,6-toluene diisocyanate; Methylenediphenyl diisocyanate; 1,5-naphthalene diisocyanate; Toridine diisocyanate; Hexamethylene-1,6-diisocyanate; Isophorone diisocyanate; Xylene diisocyanate; Cyclohexylene-1,4-diisocyanate; Lysine diisocyanate; Tetramethylene-xylene diisocyanate can be used individually or in combination of 2 or more types. Preferably isophorone diisocyanate; 2,4-toluene diisocyanate; 2,6-toluene diisocyanate; Most preferably, methylenediphenyl isocyanate or the like is used.

As said diol compound, Ethylene glycol; Propylene glycol; 1,3-butanediol; 1,4-butanediol; 1,5-pentanediol; 1,6-hexanediol; Triethylene glycol; Diethylene glycol; Tetraethylene glycol; Dipropylene glycol; Dibutylene glycol; Neopentyl glycol; 1,4-cyclohexanedimethanol; 2-methyl-1,3-pentanediol or the like may be used alone or in combination of two or more thereof. Preferably ethylene glycol; Propylene glycol; Any one or 1 or more of 1,4-butanediol is used together.

Preferably known antioxidants can be added according to known methods in the preparation of polyurethane prepolymers. As the antioxidant, for example, phenyl-beta-naphthalamine; Cysteine hydrochloride; Dibutylhydroxytoluene; Nordihydroguazaletic acid; Butylhydroxy anisole; Phosphoric acid; Citric acid; Ascorbic acid; Erythorbic acid; Propyl gallic acid, IRGANOX 1010 from Ciba Specialty Chemicals; IRGANOX 1035; IRGANOX 1076; IRGANOX 1330; IRGANOX 1425WL; IRGANOX 3114; IRGANOX B215; IRGANOX B220; IRGANOX B225; IRGANOX B561; IRGANOX B313; IRGANOX B501W; IRGANOX B900; IRGANOX B1411; IRGANOX B1412; IRGANOX PS800; IRGANOX PS802; IRGAFOS P-EPQ or the like may be used. Preferably phosphoric acid; Citric acid; Dibutylhydroxytoluene; Butylhydroxyanisole; IRGANOX 1010; IRGANOX 1035; IRGANOX 1076; Any one or two or more of IRGANOX 1330 are used together. The antioxidant is preferably added in the range of 0.05 to 5% by weight of the total weight of the polyurethane prepolymer.

(2) Preparation of Polyurethane Foamed Mixture

To 100 parts by weight of the polyurethane prepolymer prepared above, 60 to 120 parts by weight of deionized water (DIW) and 1 to 10 parts by weight of surfactant were mixed at 3,000 RPM to prepare a foamed mixture.

As the surfactant, known surfactants may be used according to known uses and methods. For example, BASF's F-68 which is an ethylene oxide / propylene oxide block copolymer; F-87; F-88; F-108; F-127 and L-580 as a silicone type surfactant; L-603; L-688; L-5420; SZ-1703; L-6900; L-3150; Y-7931; L-1580; L-5340; L-5333; L-6701; L-5740M; L-3002; L-626, DOWFAX 63N10 from Dow Chemical; DOWFAX 63N30; DOWFAX 81N13 TB; DOWFAX DF-111; DOWFAX DF-117; DOWFAX; DF-103; DOWFAX DF-104; DOWFAX DF-102 etc. can be used. The surfactant serves to control the size of the pores of the upper contact layer 11 and the inner absorbent layer 12 of the polyurethane foam dressing material and the opening ratio of the pores.

In this case, preferably, a moisturizing agent such as glycerin may be included in the foamed mixed solution. In addition, any moisturizing agent that may be applied to the human body and may have a liquid form may be used. For example, a water-soluble natural polymer may be dissolved in distilled water to prepare a liquid phase. Preferably, glycerin may be used alone in the production process.

In addition, a known superabsorbent polymer (Super Absorbent Polymer) may be included as an absorption aid to increase the absorbency of the polyurethane foam.

(3) molding production of polyurethane foam layer

The foamed mixed solution prepared above is applied onto a release paper in a thickness of 0.05 to 10 mm to obtain a polyurethane foam layer in a gel state with a tack property before curing.

After applying the foam mixture stirred at high speed in a predetermined thickness on a release paper using a coating gauge or the like, after about 1 to 2 minutes has elapsed, the polyurethane foam layer is in a gel state with a tack. Is formed. In this step, before the foamed mixed solution applied on the release paper is cured, that is, a polyurethane foam layer is formed in a state of sticky tack like gel, the next step is to proceed.

Although it does not specifically limit as a release paper, It is preferable to use the release paper processed with silicone.

Lamination

The polyurethane film layer prepared in the above step is laminated with a polyurethane foam layer having a tack (Gel) state, hot air-dried, cooled to room temperature, and then peeled off the release paper in contact with the polyurethane film layer and the release paper in contact with the foam layer. To obtain a polyurethane foam dressing material.

After laminating the polyurethane foam layer and the polyurethane film layer in the tack gel state before curing, and drying it for about 1 minute in a hot air dryer at about 100 ℃, do not use adhesive separately. You can simply combine without the need. If the polyurethane foam of the step is laminated when the gel (Tack Free Time) has passed through the gel (Gel) state, the polyurethane foam layer and the waterproof polyurethane film layer is not laminated because it should be noted.

In an embodiment of the present invention, the polyurethane prepolymer and the foamed mixed solution are stirred at a high speed of about 3,000 RPM, and then applied to a release paper treated with silicon at a constant thickness, and after about one minute, the waterproof polyurethane film and The surfaces without release paper are brought into contact with each other and dried in a 100 ° C. hot air dryer for 1 minute. After drying, the release paper in contact with the polyurethane film layer is peeled off, aged in a 70 ° C. hot air dryer for a predetermined time, and the release paper in contact with the foam layer is peeled off to obtain a polyurethane foam dressing material in a laminated state. As such, the reason for peeling off the release paper on which the waterproof polyurethane film layer is formed after drying in a hot air dryer is a phenomenon in which the polyurethane foam dressing material shrinks and shrinks when aged in a hot air dryer at 70 ° C. without being hot air dried. Curing) appears and is difficult to wind in the form of a roll, and also hinders volatilization of moisture remaining in the polyurethane foam layer. If the moisture is not volatilized properly, the exudation capacity and the absorption rate of the exudates of the wound surface contact layer 11 of the polyurethane foam dressing material are reduced. After aging for a certain period of time, the polyurethane foam dressing material shrinks to some extent. At this time, the waterproof outer film layer shrinks together, resulting in a natural wrinkle pattern. The same effect can be obtained by using a release paper such as a wrinkled release paper AR-175 (Asahirol Co., Ltd.).

Formation of Drug-Containing Layer

A solution containing a drug at a viscosity of 2,000 to 4,000 cps / 25 ° C. is applied to the foam layer of the laminated polyurethane foam dressing material of the above step to form a drug containing layer.

The solution containing the drug is dissolved or dispersed in a solvent such as deionized water (DIW), and the viscosity is adjusted to 2,000 to 4,000 cps / 25 ° C by adding a pharmaceutically acceptable excipient or viscosity control agent as necessary. Get

In the present invention, the "drug" contained in the drug-containing layer refers to all substances that can directly or indirectly help wound healing, such as moisturizers or wound healing aids, as well as substances known as conventional medicines such as antibacterial agents.

Firstly, the drug may include a known antibacterial agent to prevent infection and proliferation of various bacteria. For example, sulfadiamine may include povidone iodine, iodine, iodide ion salt, pladiomycin sulfate, acrinol, chlorohexidine, benzalkonium chloride, benzenetonium chloride, sodium fucidinate, and the like. In addition, known drugs can be included in the dressing material of the present invention for therapeutic and prophylactic purposes.

In addition, moisturizers, wound healing aids and the like may be included alone or in combination with other drugs such as the antimicrobial agents. Moisturizers and wound healing aids maintain the moist environment on the wound surface to prevent the formation of crusts and to facilitate wound healing, and also thicken the mixed solution so that drugs such as antimicrobial agents are dispersed evenly and do not sink in the liquid. It plays a role. It also serves to increase the viscosity so that the mixed solution containing the drug does not penetrate into the polyurethane foam layer. Specifically, propylene glycol alginate, methyl cellulose, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, sodium carboxymethyl starch, sodium alginate, ammonium alginate, potassium alginate, calcium alginate, sodium caseinate, guar gum, locust bean gum, xanthan gum, Cyclodextrin, gum arabic, gellan gum, carrageenan, karaya gum, casein, tarac gum, tamarind gum, tragacanth gum, pectin, glucomannan, gati gum, arabinogalactan, percelanan, pullulan, glucosamine, Carboxymethylcellulose, chitin, chitosan, sodium alginate, hyaluronic acid, amino acids, L-aspartic acid, L-aspartic acid sodium, DL-alanine, L-isoleucine, lysine hydrochloride, glycine, glycerin, L-glutamine, L-glutamic acid, L- Sodium Glutamate, Pyrizine, L-Threonine, Sericin, Serine, L-Tyrosine, Heparin, Sodium Chondroitin Sulfate, Sodium Alginate, Gel Such as tin, fibroblast growth factor (FGF), between the fiber growth factor (HGF), epidermal cell growth factor (EGF) granulation accelerator such as may be contained in the mixed solution.

In addition, sugars having bacteriostatic and granulative growth may also be included as wound healing aids. Sucrose, sorbitol, mannitol, fructose, glucose, xylitol, lactose, maltose, maltitol, trehalose and the like can be used.

In addition, natural substances that have anti-inflammatory, antibacterial, antifungal or skin regeneration effects may also be included. For example, bioflavonoids derived from Teatree oil, Sophora Angustifolia Extract, Iris Extract, Glycyrrhiza Glabra Extract, Grapefruit (seed) extract; Naringin; Polypeptides; Asiatic acid from Tocopherols, Centella Asiatica; Madecaic Acid, β-Glucan Extracted from Mushroom, Neem Extract, Witch Hazel Extract, Allantoin, Portulace Oleracea Extract Natural ingredients, such as Ponciri Fructus Extract, Phytosphingosine, and Aloe Extract, may be used alone or in combination.

The solvent may be any pharmaceutically acceptable solvent as long as it can dissolve or disperse the selected drug. Although not particularly limited, deionized water (DIW), ethanol, methanol, and the like may be used as the solvent, and deionized water (DIW) may be preferably used.

Excipients known in the pharmaceutical art can be used as excipients, for example glycerin and the like.

As the viscosity modifier, any pharmaceutically acceptable viscosity modifier may be used, and for example, carboxymethyl cellulose, sodium alginate, carrageenan, or the like may be used.

Drugs may be included alone or in combination of two or more at known doses. In general, the drug may be included in the range of 2 to 50 parts by weight based on 100 parts by weight of a solvent such as deionized water (DIW). In addition to helping wound healing, drugs such as moisturizers and wound healing aids included in the drug-containing layer increase the viscosity of the solution and also act as thickeners and stabilizers to prevent other drugs such as antimicrobial agents from being dispersed throughout and to sink in the liquid phase. . Therefore, if the drug, such as moisturizers, wound healing aids are properly included, it is possible to adjust the viscosity of the solution containing the drug in the range of 2,000 to 4,000 cps / 25 ℃ even without using a separate excipient or viscosity regulator. At this time, if the viscosity is less than 2,000cps / ° C drug-containing liquid solution soaked into the polyurethane foam dressing material may cause a problem, if more than 4,000cps / 25 ° C to apply the drug-containing layer on the surface of the polyurethane foam dressing material Can be difficult.

Application | coating can be performed, for example using the knife roll coating method, a release paper shaping | molding process, etc., but a coating method is not specifically limited to this. In one embodiment of the present invention used a knife roll coating method. On the surface of the roll in the form of engraving a pattern of a certain shape (for example, round or line) intaglio, apply the solution containing the drug prepared above, scrape with a knife and then contact the surface of the polyurethane foam dressing material prepared above After coating to make a coating and dried for 30 seconds in a 100 ℃ hot air dryer to form a drug-containing layer. The viscosity of the mixed solution suitable for application at this time is in the range of 2,000 to 4,000 cps / 25 ° C. If the viscosity is 2,000 cps or less, there is a problem that the mixed solution does not adhere well to the fine surface of the roll, and if it is 4,000 cps or more, it may be difficult to transfer the mixed solution to the polyurethane foam dressing material.

In addition to this, the mixed solution prepared above is applied onto a release paper embossed or perforated release paper with a uniform pattern, and then coated using a coating gauge, etc., and then laminated with a polyurethane foam dressing material, followed by drying in a hot air dryer. Can also be used. Those skilled in the art will be able to select a suitable method in consideration of process conditions or product condition.

The drug-containing layer 30 may be formed in various forms by various methods as described above. 1d to 1f are examples of the formation of the drug-containing layer 30, FIG. 1d is a surface of the polyurethane foam dressing material with the drug-containing layer 30 applied in a separate circular form, and FIG. 1e is the opposite of the form of FIG. 1d. Circularly isolated to the surface of the polyurethane foam dressing material in the state that the drug-containing layer 30 is not applied, Figure 1f is the surface of the polyurethane foam dressing material to form a state in which the drug-containing layer 30 is isolated in a continuous linear form. . 1D to 1F are exemplary forms, and the drug-containing layer of the present invention may be formed in various forms such as a simple linear form (straight line, vertical line, inclined line, curved form, etc.) that is not isolated.

In the dressing material in which the drug-containing layer is formed on the polyurethane foam dressing material, the area of the drug-containing layer is preferably 30 to 90% of the total area. If the area is less than 30%, the drug may not be evenly delivered to the wound surface, and if the area is more than 90%, there may be a problem that the absorption of exudate is slowed down due to the drug-containing layer.

 Polyurethane foam dressing material having a drug-containing layer prepared according to the present invention, the outer film layer made of a non-porous waterproof polyurethane film; A foam layer formed on the outer film layer and made of polyurethane foam; It includes a drug-containing layer formed on the foam layer and containing the drug in a non-mixed state with the polyurethane forming the foam layer. The structure of the polyurethane foam dressing material according to the present invention will be described with reference to the accompanying drawings.

Figure 1a is a schematic cross-sectional view of the polyurethane foam dressing material produced in accordance with the present invention, the outer film layer 20 made of a non-porous waterproof polyurethane film; A foam layer (10) made of polyurethane foam; The drug containing layer 30 containing a drug is formed sequentially.

The outer film layer 20 is formed of a moisture-permeable and waterproof polyurethane film, and forms the outermost layer of the dressing material of the present invention, that is, the outermost layer opposite to the surface in contact with the skin. The outer film layer 20 has a high moisture permeability of 400 to 3,000 g / m 2 / day (relative humidity 10 to 90%, 37 ° C., Desiccant Method) to prevent invasion of bacteria and bacteria from the outside. To prevent external leakage of exudate, and to create a moist environment on the wound surface.

The polyurethane foam layer 10 is made of a polyurethane foam in which polyurethane is foamed on a sheet. The foam layer 10 again has a wound surface contact layer 11 having fine open pores having a diameter of 1 to 50 μm and an inner absorbent layer 12 having a plurality of open pores having a diameter of 1 to 600 μm. It is divided into two-layer structure. This two-layer structure, when the polyurethane prepolymer and the foamed mixture is stirred at a high speed in the manufacturing process and then applied to the release paper with a certain thickness, finer open cells are formed in comparison with the parts not in contact with the release paper. It is made naturally by the formation of a layer in the form of a film. FIG. 1B is a schematic surface diagram of the skin contact layer 11, and FIG. 1C is a schematic surface diagram of the internal absorbent layer 12. As shown in FIG. The wound surface contact layer 11 has micropores having a diameter of 1 to 50 µm, serves to absorb exudates, and has a wound surface non-adhesive property. The inner absorbent layer 12 has a plurality of open pores having a diameter of 1 to 600 µm, can absorb and store 100 to 1,000 wt% of its own weight, and has a density in the range of 0.1 to 0.5 g / cm 3.

The drug containing layer 30 is formed on the foam layer, and contains the drug in a state in which it is not mixed with the polyurethane forming the foam layer. The drug-containing layer 30 is formed in the range of 30 to 90% of the total area of the foam layer, the thickness may have a range of 10㎛ ~ 1mm. As illustrated in FIGS. 1D to 1F, the drug-containing layer 30 may be formed in various forms.

Figure 2a to 2c is a scanning electron micrograph of the polyurethane foam dressing material according to the present invention, Figure 2a is a photograph of the wound surface contact layer 11, Figure 2b is a photograph of the inner absorbent layer 12, Figure 2c is the outer It is a photograph of the film layer 20. It can be seen that the inner absorbent layer is larger than the wound surface contact layer and has many open pores. It can be seen that the outer film layer is non-porous to allow waterproofing.

Hereinafter, the present invention will be described in more detail with reference to specific examples. However, the scope of the present invention is not limited by the following examples, and those skilled in the art to which the present invention pertains should be within the equivalent scope of the technical concept of the present invention and the claims to be described below. Of course, various modifications and variations are possible.

Polyurethane Prepolymer  synthesis( Synthesis Example  One)

The polyurethane prepolymer was synthesized according to the conditions and methods shown in Table 1 below.

Breathable  Polyurethane synthesis ( Synthesis Example  2)

The moisture-permeable waterproof polyurethane was synthesized under the conditions and methods of the following Table 2.

Breathable  Polyurethane film Production Example

The moisture-permeable waterproof polyurethane film is 50 parts by weight of methyl ethyl ketone, 15 parts by weight of dimethylformamide, and 5 parts by weight of pigment (SF-Pink 1013TM) in 100 parts by weight of the water-repellent waterproof polyurethane resin prepared in Synthesis Example 2. The mixture was stirred to prepare a polyurethane mixture.

The prepared polyurethane mixture was applied to the matte release paper (Yulchon Chemical Co., Ltd.) using a thickness gauge to a certain thickness, and then dried in a 100 ° C. hot air dryer for 30 minutes to form a moisture-permeable waterproof polyurethane film on one side of the matte release paper. . It was 30 micrometers in thickness of the produced moisture-permeable waterproof polyurethane film.

Production Example  One

(1) Polyurethane foam dressing material is 100 parts by weight of the polyurethane prepolymer prepared in Synthesis Example 1, 80 parts by weight of DI water, 20 parts by weight of glycerin as a moisturizer, 2 parts by weight of F-68 (BASF) as a surfactant After the addition, the mixture was stirred at 3,000 RPM for 10 seconds, and then applied to a silicone release paper (Yulchon Chemical Co., Ltd.) and coated using a 2.2 mm thick gauge.

(2) After 1 minute of coating as described above, a 30 μm thick film prepared in the moisture-permeable waterproof polyurethane film manufacturing example was given a 2.2 mm thickness gap and laminated, followed by a 100 ° C. hot air dryer. Dried for 1 min.

(3) After drying, peel off the matte release paper on which the moisture-permeable waterproof polyurethane film was formed, and aged for 24 hours in a 70 ° C. hot air dryer, followed by peeling off the release paper in contact with the foam layer, and the thickness of the polyurethane foam dressing material was 2 mm. The product whose outer film layer was 30 micrometers was produced.

(4) 100 parts by weight of deionized water (DIW), 2 parts by weight of sodium alginate, 3 parts by weight of sodium fucidinate, and 3 parts by weight of centalasiatica extract were added and stirred to prepare a mixed solution, using a knife roll coating method. In the form of Figure 1b, a polyurethane foam dressing material having a drug containing layer having an area of 30% of the total area and a thickness of 0.2 mm was prepared.

Physical properties of the prepared polyurethane foam dressing material were measured by the method exemplified below, and the measured experimental results are shown in Table 3 below.

Experiment method

① Mechanical Properties (tensile strength, elongation)

Using a universal test machine (Instron), the load cell (Load cell) 50N, the width of the specimen 20mm, the length of the specimen (Gauge Length) 30mm, the cross head speed (100mm / min) Measured.

② Absorbance (%)

Take the dressing material in the size of 5cm × 5cm and leave it at room temperature for 24 hours, measure the initial weight (A), impregnate and store it in 37 ℃ distilled water for 24 hours, take it out, wipe the water off the surface, and then weigh the weight (B). Measured. Finally, the following equation was used.

Absorbance (%) = (B-A) / A × 100

③ moisture permeability

The thermohygrostat was measured according to ASTM E 96-94 (Desiccant Method), wherein the thermohygrostat was 37 ° C and the relative humidity was 80%.

④ Morphology

The pore shape and size of the polyurethane foam dressing material of the present invention and the thickness of the film layer were measured using a scanning electron microscope.

⑤ Measurement of wound healing effect

Experiments were performed using 250-300 g rats at 6-8 weeks of age. Lett was anesthetized with rambutal. Intra-tracheal intubation and oxygen supply were allowed to spontaneously breathe indoor air. The flanks were cut and the hair was completely removed with an epilator. The surgical site was disinfected with povidone and alcohol, and aseptic surgery was performed. After making 80π㎡ of skin defect on the back, wash the wound with physiological saline and wipe it with dry gauze, attach the dressing material about 1cm wider than the wound, cover 2 gauze on it and prevent the dressing from falling off. In order to fix the body lightly with an elastic bandage. The dressing was changed 3, 6, 9, 12, and 15 days after dressing. The degree of epithelialization of the skin defect area over time, the detachment of new tissue during dressing change, and the tissue biopsy using optical microscope were used for wound healing. Was measured.

Production Example  2

(1) Polyurethane foam dressing material is 100 parts by weight of the polyurethane prepolymer prepared in Synthesis Example 1, 80 parts by weight of DI water, 20 parts by weight of glycerin as a moisturizer, 2 parts by weight of F-68 (BASF) as a surfactant After the addition, the mixture was stirred at 3,000 RPM for 10 seconds, and then applied to a silicone release paper (Yulchon Chemical Co., Ltd.) and coated using a 2.2 mm thick gauge.

(2) After 1 minute of coating as described above, give a 30 mm thick film prepared in the moisture-permeable water-proof polyurethane film manufacturing example and give a 2.2 mm thickness gap and laminating it immediately. Dry in the dryer for 1 minute.

(3) After drying, peel off the matte release paper on which the moisture-permeable waterproof polyurethane film was formed, and aged for 24 hours in a 70 ° C. hot air dryer, followed by peeling off the release paper in contact with the foam layer, and the thickness of the polyurethane foam dressing material was 2 mm. The product whose outer film layer was 30 micrometers was produced.

(4) To 100 parts by weight of DI water, 2 parts by weight of sodium alginate, 3 parts by weight of sodium fucidinate, and 3 parts by weight of centalasiatica extract were added to stir to prepare a mixed solution, followed by knife roll coating. To prepare a polyurethane foam dressing material in the form of a drug containing layer having a drug containing layer of 50% of the total area and a thickness of 0.2mm in the form of Figure 1b.

The physical properties of the prepared polyurethane foam dressing material were measured by the method illustrated in Preparation Example 1, and the measured experimental results are shown in Table 3 below.

Production Example  3

(1) Polyurethane foam dressing material is 100 parts by weight of the polyurethane prepolymer prepared in Synthesis Example 1, 80 parts by weight of DI water, 20 parts by weight of glycerin as a moisturizer, 2 parts by weight of F-68 (BASF) as a surfactant After the addition, the mixture was stirred at 3,000 RPM for 10 seconds, and then applied to a silicone release paper (Yulchon Chemical Co., Ltd.) and coated using a 2.2 mm thick gauge.

(2) After 1 minute of coating as described above, give a 30 mm thick film prepared in the moisture-permeable water-proof polyurethane film manufacturing example and give a 2.2 mm thickness gap and laminating it immediately. Dry in the dryer for 1 minute.

(3) After drying, peel off the matte release paper on which the moisture-permeable waterproof polyurethane film was formed, and aged for 24 hours in a 70 ° C. hot air dryer, followed by peeling off the release paper in contact with the foam layer, and the thickness of the polyurethane foam dressing material was 2 mm. The product whose outer film layer was 30 micrometers was produced.

(4) To 100 parts by weight of DI water, 2 parts by weight of sodium alginate, 3 parts by weight of sodium fucidinate, and 3 parts by weight of centalasiatica extract were added to stir to prepare a mixed solution, followed by knife roll coating. To prepare a polyurethane foam dressing material in the form of a drug containing layer having a drug containing layer of 80% of the total area and a thickness of 0.2mm in the form of Figure 1b.

The physical properties of the prepared polyurethane foam dressing material were measured by the method illustrated in Preparation Example 1, and the measured experimental results are shown in Table 3 below.

Production Example  4

(1) Polyurethane foam dressing material is 100 parts by weight of the polyurethane prepolymer prepared in Synthesis Example 1, 80 parts by weight of DI water, 20 parts by weight of glycerin as a moisturizer, 2 parts by weight of F-68 (BASF) as a surfactant After the addition, the mixture was stirred at 3,000 RPM for 10 seconds, and then applied to a silicone release paper (Yulchon Chemical Co., Ltd.) and coated using a 2.2 mm thick gauge.

(2) After 1 minute of coating as described above, give a 30 mm thick film prepared in the moisture-permeable water-proof polyurethane film manufacturing example and give a 2.2 mm thickness gap and laminating it immediately. Dry in the dryer for 1 minute.

(3) After drying, peel off the matte release paper on which the moisture-permeable waterproof polyurethane film was formed, and aged for 24 hours in a 70 ° C. hot air dryer, followed by peeling off the release paper in contact with the foam layer, and the thickness of the polyurethane foam dressing material was 2 mm. The product whose outer film layer was 30 micrometers was produced.

(4) To 100 parts by weight of DI water, 2 parts by weight of sodium alginate, 3 parts by weight of sodium fucidinate, and 3 parts by weight of centalasiatica extract were added to stir to prepare a mixed solution, followed by knife roll coating. 1b, a polyurethane foam dressing material having a drug containing layer having a thickness of 90% of the total area and a thickness of 0.2 mm was formed in the form of FIG.

The physical properties of the prepared polyurethane foam dressing material were measured by the method illustrated in Preparation Example 1, and the measured experimental results are shown in Table 3 below.

Comparative Production Example  One

(1) Polyurethane foam dressing material is 100 parts by weight of the polyurethane prepolymer prepared in Synthesis Example 1, 80 parts by weight of deionized water (DIW), 20 parts by weight of glycerin as a moisturizing agent, F-68 (BASF) 2 as a surfactant By weight, 3 parts by weight of sodium fucidinate, 3 parts by weight of Centala asiatica extract was added and stirred at 3,000 RPM for 10 seconds, and then applied to a silicone release paper (Yulchon Chemical Co., Ltd.) and coated using a 2.2 mm thick gauge.

(2) After 1 minute of coating as described above, give a 30 mm thick film prepared in the moisture-permeable water-proof polyurethane film manufacturing example and give a 2.2 mm thickness gap and laminating it immediately. Dry in the dryer for 1 minute.

(3) After drying, the matte release paper with the moisture-permeable polyurethane film formed was peeled off and aged in a 70 ° C. hot air dryer for 24 hours, and the polyurethane foam dressing material had a thickness of 2 mm and the moisture-repellent waterproof outer film layer was 30 μm. Was prepared.

The physical properties of the prepared polyurethane foam dressing material were measured by the method illustrated in Preparation Example 1, and the measured experimental results are shown in Table 3 below.

Comparative Production Example  2

(1) The polyurethane foam dressing material is 100 parts by weight of the polyurethane prepolymer prepared in Synthesis Example 1, 80 parts by weight of DI water, 2 parts by weight of F-68 (BASF) as a surfactant, 20 parts by weight of glycerin as a moisturizer. After the addition, the mixture was stirred at 3,000 RPM for 10 seconds, and then applied to a silicone release paper (Yulchon Chemical Co., Ltd.) and coated using a 2.2 mm thick gauge.

(2) After 1 minute of coating as described above, give a 30 mm thick film prepared in the moisture-permeable water-proof polyurethane film manufacturing example and give a 2.2 mm thickness gap and laminating it immediately. Dry in the dryer for 1 minute.

(3) After drying, peel off the matte release paper on which the moisture-permeable waterproof polyurethane film was formed, and aged for 24 hours in a 70 ° C. hot air dryer, followed by peeling off the release paper in contact with the foam layer, and the thickness of the polyurethane foam dressing material was 2 mm. The product whose outer film layer was 30 micrometers was produced.

(4) To 100 parts by weight of deionized water (DIW), 2 parts by weight of sodium alginate, 3 parts by weight of sodium fucidinate, and 3 parts by weight of centalasiatica extract were added to prepare a mixed drug solution, followed by knife roll coating. In the form of Figure 1b, in the foam layer of the polyurethane foam dressing material prepared in the above (3) to form a drug containing layer 10% of the total area of the foam layer and 0.2mm in thickness.

The physical properties of the prepared polyurethane foam dressing material were measured by the method illustrated in Preparation Example 1, and the measured experimental results are shown in Table 3 below.

Comparative Production Example  3

(1) Polyurethane foam dressing material is 100 parts by weight of the polyurethane prepolymer prepared in Synthesis Example 1, 80 parts by weight of DI water, 20 parts by weight of glycerin as a moisturizer, 2 parts by weight of F-68 (BASF) as a surfactant After the addition, the mixture was stirred at 3,000 RPM for 10 seconds, and then applied to a silicone release paper (Yulchon Chemical Co., Ltd.) and coated using a 2.2 mm thick gauge.

(2) After 1 minute of coating as described above, a 30 μm thick film prepared in the moisture-permeable water-resistant polyurethane film manufacturing example was given a 2.2 mm thickness gap and laminated, followed by a 100 ° C. hot air dryer. Dried for 1 min.

(3) After drying, peel off the matte release paper on which the moisture-permeable waterproof polyurethane film was formed, and aged for 24 hours in a 70 ° C. hot air dryer, followed by peeling off the release paper in contact with the foam layer, and the thickness of the polyurethane foam dressing material was 2 mm. The product whose outer film layer was 30 micrometers was produced.

(4) To 100 parts by weight of deionized water (DIW), 2 parts by weight of sodium alginate, 3 parts by weight of sodium fucidinate, and 3 parts by weight of centalasiatica extract were added to prepare a mixed solution, followed by stirring on a release paper treated with silicone. After coating and coating using the coating gauge, the polyurethane dressing material is laminated and dried in a hot air dryer, and then the polyurethane foam dressing material is formed with a drug containing layer having a thickness of 100% of the total area and a thickness of 0.2 mm. Prepared.

The physical properties of the prepared polyurethane foam dressing material were measured by the method illustrated in Preparation Example 1, and the measured experimental results are shown in Table 3 below.

Comparative example  One

Commercially available Mediform ™ (Ildong Pharmaceutical Co., Ltd.) was used in the experiment for physical property comparison. Physical properties were measured by the method illustrated in Preparation Example 1, and the results are shown in Table 6 below.

Comparative example  2

Polymem ™ (Shinshin Pharmaceutical Co., Ltd.) was used in the experiment for physical property comparison. Physical properties were measured by the method illustrated in Preparation Example 1, and the results are shown in Table 6 below.

Comparative example  3

Commercially available Care Foam ™ (Hanmi Pharm.) Was used for the comparison of properties. Physical properties were measured by the method illustrated in Preparation Example 1, and the results are shown in Table 6 below.

*: Condition = 37 ° C, 80% RH

**: Existing Product

E: Excellent G: Good F: Fair P: Poor

As can be seen from Table 3, when the area of the drug-containing layer is 30 to 90%, the wound healing effect is excellent. In Comparative Preparation Example 3, the drug-containing layer covered the whole, which prevented the exudation of the exudates during the dressing exchange, and the antimicrobial agent was in contact with the wound surface. In addition, Comparative Preparation Examples 1 and 2 were excellent in the rate of exudate absorption, but the healing rate of the wound was not as good as in the other Preparation Examples. Particularly, in Preparation Examples 2 and 3, re-epithelialization and wound shrinkage were very excellent, and the wound healing rate was also superior to other Preparation Examples, Comparative Preparation Examples, and Comparative Examples.

Comparative Production Example  4 to 6

(1) Polyurethane foam dressing material is 100 parts by weight of the polyurethane prepolymer prepared in Synthesis Example 1, 80 parts by weight of deionized water (DIW), 20 parts by weight of glycerin as a moisturizing agent, F-68 (BASF) 2 as a surfactant By weight, silver sulfadiazine was added as follows, stirred for 10 seconds at 3,000 RPM, and then applied to a silicone release paper (Yulchon Chemical Co., Ltd.) and coated using a 2.2 mm thick gauge.

Comparative Example 4 (Sample 1): Silver sulfadiazine 10 μg / cm 2

Comparative Example 5 (Sample 2): Silver sulfadiazine 30 μg / cm 2

Comparative Example 6 (Sample 3): Silver sulfadiazine 60 μg / cm 2

(2) After 1 minute of coating as described above, give a 30 mm thick film prepared in the moisture-permeable water-proof polyurethane film manufacturing example and give a 2.2 mm thickness gap and laminating it immediately. Dry in the dryer for 1 minute.

(3) After drying, the matte release paper with the moisture-permeable polyurethane film formed was peeled off and aged in a 70 ° C. hot air dryer for 24 hours, and the polyurethane foam dressing material had a thickness of 2 mm and the moisture-repellent waterproof outer film layer was 30 μm. Was prepared.

The drug release test was performed to find the release rate and release amount of the drug contained in the prepared polyurethane foam dressing material. The experiment proceeded to the experimental method presented below to investigate the drug release behavior for 48 hours, the results are shown in Table 4 and FIG.

Experiment method

(1) Finding Maximum Absorption Wavelength

A solution prepared at the concentration of 0.2mg / ml by adding silver sulfadiazine to the pH7.4 phosphate buffer solution. Using the UV Spectrometer (Jasco, V-550), the absorption spectrum was obtained at 200∼1,000nm and the maximum absorption peak (254 nm) is obtained.

(2) Find the quantitative curve

Silver sulfadiazine was prepared in distilled water at a concentration of 0.01, 0.05, 0.1, 0.25, 0.5, 1.0 mg / ml, and then the slope (B) and the section (Y) were obtained after drawing a quantitative curve at 254 nm. It is performed for each sample.

Conc = B × ABS + Y

(3) experiment

Release the polyurethane foam dressing containing silver sulfadiazine into 2cm × 2cm size and release the drug while maintaining the condition of 37 ± 5 ℃ and 100RPM in the shaking incubator (DA-SI-LL, Dong-A Science). The test was conducted. Each specimen was sampled using a micro syringe at a predetermined time interval 3ml, and the same temperature was added to the same temperature after sampling to maintain the sink condition (Sink Condition). The concentration of the sample taken was detected at 254 nm using a UV spectrometer and graphically expressed as the amount released (μg / cm 2) relative to the total amount contained in the polyurethane foam dressing material. The results are shown in Table 4 and FIG.

Production Example  5 to 7

(1) The polyurethane foam dressing material is 100 parts by weight of the polyurethane prepolymer prepared in Synthesis Example 1, 80 parts by weight of DI water, 2 parts by weight of F-68 (BASF) as a surfactant, 20 parts by weight of glycerin as a moisturizer. After the addition, the mixture was stirred at 3,000 RPM for 10 seconds, and then applied to a silicone release paper (Yulchon Chemical Co., Ltd.) and coated using a 2.2 mm thick gauge.

(2) After 1 minute of coating as described above, give a 30 mm thick film prepared in the moisture-permeable water-proof polyurethane film manufacturing example and give a 2.2 mm thickness gap and laminating it immediately. Dry in the dryer for 1 minute.

(3) After drying, the matte release paper with the moisture-permeable polyurethane film formed was peeled off and aged in a 70 ° C. hot air dryer for 24 hours, and the polyurethane foam dressing material had a thickness of 2 mm and the moisture-repellent waterproof outer film layer was 30 μm. Was prepared.

(4) To 100 parts by weight of deionized water (DIW), 2 parts by weight of sodium alginate and silver sulfadiazine were added and stirred to prepare a mixed drug solution, and then in the form of FIG. 1B using the knife roll coating method. In the foam layer of the polyurethane foam dressing material prepared in (3), a drug containing layer having a thickness of 80% and a thickness of 0.2 mm was formed.

Example 5 (Sample 4): Silver sulfadiazine 10 μg / cm 2

Example 6 (Sample 5): Silver sulfadiazine 30 μg / cm 2

Example 7 (Sample 6): Silver sulfadiazine 60 μg / cm 2

The release rate and release amount of the drug contained in the prepared polyurethane foam dressing material were measured by the method exemplified above, and the measurement results are shown in Table 4 and FIG. 3.

As can be seen in Table 4 and Figure 3, when the same amount of silver sulfadiazine was added, the manufacturing method of coating on the surface was better in the drug release amount than the manufacturing method added to the inside of the polyurethane dressing material. Comparing samples 3 and 5, it can be seen that even though the amount of silver sulfadiazine was added twice in the polyurethane dressing material, the release amount was almost the same as that of adding half of it to the surface of the dressing material. It is believed that this is because the drug is present in an isolated form in the urethane polymer due to the nature of the foam structure, thereby preventing the drug from being released. Comparing samples 1 and 4, the smaller the addition amount, the greater the difference in drug release amount. Therefore, the new manufacturing method of coating the drug on the surface of the polyurethane dressing material, such as the antibacterial agent in addition to the manufacturing method of the drug coating on the surface of the drug production is excellent even if the drug is used less expensive It can be seen that it can reduce the production cost and can deliver the drug smoothly to the wound.

The present invention provides a polyurethane foam dressing material including a new type of drug-containing layer that improves the method of adding a drug to the conventional polyurethane foam dressing material. Polyurethane foam dressing material having a drug-containing layer of the present invention can be smoothly released through a separate drug-containing layer separated from the foam layer can prevent the waste of the drug due to the excessive addition, the relationship with the presence or absence of exudate The release of the drug can be achieved without the need for a sufficient supply of the drug in the wound or in the late stages of the wound, with little or no exudate. In addition, the polyurethane foam dressing material manufacturing method of the present invention can be prepared by varying the area and thickness of the drug-containing layer appropriately according to the concentration, type, wound healing effect of the drug, so that various forms of foam dressing material Manufacturing and application are possible.

Claims (12)

(a) 20 to 70 parts by weight of methyl ethyl ketone, 5 to 30 parts by weight of dimethylformamide, and 1 to 10 parts by weight of pigment are added to 100 parts by weight of polyurethane resin, followed by stirring, removing bubbles and coating on a release paper, followed by drying. Obtaining a non-porous waterproof polyurethane film layer; (b) A foam mixture obtained by mixing 60 to 120 parts by weight of deionized water (DIW) and 1 to 10 parts by weight of surfactant at a high speed to 100 parts by weight of polyurethane prepolymer on a release paper with a thickness of 0.05 to 10 mm before curing. Obtaining a polyurethane foam layer in a gel state having a tack property; (c) The polyurethane film layer obtained in (a) and the polyurethane foam layer in the gel state obtained in (b) are laminated, hot-air dried, cooled to room temperature, and then contacted with the polyurethane film layer and the foam layer. Peeling the release paper to obtain a polyurethane foam dressing material; And (d) a polyurethane foam dressing having a drug-containing layer comprising applying a solution containing a drug at a viscosity of 2,000 to 4,000 cps / 25 ° C. to the foam layer of the polyurethane foam dressing material obtained in (c) above to form a drug-containing layer. Method of making ash. The method according to claim 1, wherein the drug-containing layer is formed on the foam layer within a range of 30 to 90% of the foam layer area. The method of claim 2, wherein the drug-containing layer has a thickness in the range of 10 μm to 1 mm. The method according to claim 3, wherein the drug-containing solution is coated on the foam layer by a knife roll coating method to form a drug-containing layer. According to claim 3, The solution containing the drug, (a) 2 to 50 parts by weight of the drug; (b) 100 parts by weight of a solvent selected from deionized water (DIW), methanol and ethanol; (c) 20 to 40 parts by weight of excipients; And (d) 1 to 10 parts by weight of a viscosity modifier selected from carboxymethyl cellulose, sodium alginate and carrageenan. The method of any one of claims 1 to 5, wherein the drug comprises: teatree oil; Sophora Angustifolia Extract; Iris Extract; Glycyrrhiza Glabra Extract; Grapefruit (seed) extract; Centella Asiatica extract; Neem Extract (Neem Extract); Witch Hazel Extract; Portulace Oleracea Extract; Ponciri Fructus Extract; Aloe extracts; Sodium fucidinate; Silver sulfadiazine; Sucrose; Sorbitol; Mannitol; fruit sugar; glucose; Xylitol; Lactose; Maltose; Maltitol; Trehalose; The method of claim 2, characterized in that the selected from the group consisting of povidone and petrolatum. delete An outer film layer made of a non-porous waterproof polyurethane film; A foam layer formed on the outer film layer and made of polyurethane foam; And a drug-containing layer formed on the foam layer and containing the drug in a state in which it is not mixed with the polyurethane forming the foam layer, wherein the drug-containing layer is formed on the foam layer within a range of 30 to 90% of the foam layer area. Urethane foam dressing. 9. The polyurethane foam dressing material according to claim 8, wherein the drug-containing layer has a thickness in the range of 10 µm to 1 mm. The method of claim 8, wherein the foam layer is wound surface contact layer (11) formed with fine open pores (Open Cell) of 1 to 50㎛ diameter; A polyurethane foam dressing material, comprising a two-layer structure of an inner absorbent layer 12 having open pores having a diameter of 1 to 600 µm. The solution according to any one of claims 8 to 10, wherein the solution containing the drug is (a) 2 to 50 parts by weight of the drug; (b) 100 parts by weight of a solvent selected from deionized water (DIW), methanol and ethanol; (c) 20 to 40 parts by weight of excipients; And (d) 1 to 10 parts by weight of a viscosity modifier selected from carboxymethyl cellulose, sodium alginate and carrageenan. The method of claim 11, wherein the drug comprises: teatree oil; Sophora Angustifolia Extract; Iris Extract; Glycyrrhiza Glabra Extract; Grapefruit (seed) extract; Centella Asiatica extract; Neem Extract (Neem Extract); Witch Hazel Extract; Portulace Oleracea Extract; Ponciri Fructus Extract; Aloe extracts; Sodium fucidinate; Silver sulfadiazine; Sucrose; Sorbitol; Mannitol; fruit sugar; glucose; Xylitol; Lactose; Maltose; Maltitol; Trehalose; Polyurethane foam dressing material, characterized in that selected from the group consisting of povidone and petrolatum.

Images